2K4 Stock Overview
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PhaseBio Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.08 |
| 52 Week High | US$1.45 |
| 52 Week Low | US$0.053 |
| Beta | 2.52 |
| 1 Month Change | 0% |
| 3 Month Change | 15.94% |
| 1 Year Change | -93.65% |
| 3 Year Change | -98.17% |
| 5 Year Change | n/a |
| Change since IPO | -98.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2K4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.3% | -2.5% |
| 1Y | -93.7% | -19.4% | -0.4% |
Return vs Industry: 2K4 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 2K4 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 2K4 volatility | |
|---|---|
| 2K4 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2K4 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2K4's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 60 | Jonathan Mow | phasebio.com |
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension.
PhaseBio Pharmaceuticals, Inc. Fundamentals Summary
| 2K4 fundamental statistics | |
|---|---|
| Market cap | €139.25k |
| Earnings (TTM) | -€95.74m |
| Revenue (TTM) | €761.56k |
0.2x
P/S Ratio0.0x
P/E RatioIs 2K4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2K4 income statement (TTM) | |
|---|---|
| Revenue | US$818.00k |
| Cost of Revenue | US$87.70m |
| Gross Profit | -US$86.88m |
| Other Expenses | US$15.96m |
| Earnings | -US$102.84m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.06 |
| Gross Margin | -10,620.78% |
| Net Profit Margin | -12,572.13% |
| Debt/Equity Ratio | -3.5% |
How did 2K4 perform over the long term?
See historical performance and comparison